Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents

Shandong University

Status: Completed

Conditions: Invasive Fungal Infections

Treatments: Drug: Caspogunfin

Study type: Observational

Funder types: Other

Identifiers

NCT05881109

caspofungin-001

Details and patient eligibility

About

Caspofungin (CAS) is used to prevent and treat invasive fungal infections patients older than 3 months. However, the optimal dosing strategy of CAS is lacking in adolescents from 12 to 17 years old, especially those undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), who are vulnertable to fungal infections. The study aimed to establish a population pharmacokinetic (PPK) model and assess the dosing schemes of CAS in adolescents with allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Enrollment: 30 patients

Sex: All

Ages: 12 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The adolescents (12 - 17 years) underwent allo-HSCT
• Use caspofungin for the prevention or treatment of fungal infections

Exclusion criteria

• Intolerable to caspofungin
• Participate into other clinical studies
• There are conditions that researchers do not consider it appropriate to join the research.